About Advaxis, Inc.
Advaxis (NASDAQ: ADXS) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
|
|
|
11-50 employees
View all Advaxis, Inc. employees
|
|
Biotechnology
|
|
305 College Rd East, Princeton, NJ 08540, US
|
|
2002
|
|
Personalized Medicine, Prostate Cancer, Cervical Cancer, Oncology, Immunotherapy, Infectious Disease, Hpv, Head And Neck Cancer, Anal Cancer, Microcap
|
Advaxis, Inc. Alternatives
Frequently Asked Questions about Advaxis, Inc.
Who is the CEO of Advaxis, Inc.?
Daniel J O'connor is the CEO of Advaxis, Inc..
Advaxis, Inc. Staff Directory
Search Advaxis, Inc. Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Search Portal
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
